Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
RLMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $3.98
Previous CloseN/A
Volume447.03K
Average Volume (3M)1.16M
Market Cap
$55.43M
Enterprise Value-$694.61K
Total Cash (Recent Filing)$20.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Nov 06, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding33,191,624
10 Day Avg. Volume1,325,530
30 Day Avg. Volume1,164,125
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$1.00Price Target Upside-37.50% Downside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessNDV-01 for high-grade non-muscle invasive bladder cancer showed an overall response rate of 85% and high-grade recurrence-free survival in patients with papillary disease of 83%.
Competitive AdvantageNDV-01's novel sustained-release formulation could have blockbuster potential due to its ease of administration and increased efficacy.
Market OpportunityThe in-licensing of NDV-01 for treating NMIBC represents a multi-billion opportunity for Relmada Therapeutics Inc.
Bears Say
Development Re-evaluationThe company is re-evaluating further development of ‘P11 (novel psilocybin) as part of its prioritization efforts.
Uncertain Financial OutlookThe company ended the year with $27M in cash, and additional data and updates from the pipeline are awaited before making any substantive comments regarding the pipeline assets.
Valuation ConcernsAt this point, the product is not being added into the valuation, and the recommendation remains Market Perform.
Relmada Therapeutics News
RLMD FAQ
What was Relmada Therapeutics’s price range in the past 12 months?
Relmada Therapeutics lowest stock price was $0.24 and its highest was $3.98 in the past 12 months.
What is Relmada Therapeutics’s market cap?
Relmada Therapeutics’s market cap is $55.43M.
When is Relmada Therapeutics’s upcoming earnings report date?
Relmada Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 48 days.
How were Relmada Therapeutics’s earnings last quarter?
Relmada Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.46 by $0.16.
Is Relmada Therapeutics overvalued?
According to Wall Street analysts Relmada Therapeutics’s price is currently Overvalued.
Does Relmada Therapeutics pay dividends?
Relmada Therapeutics does not currently pay dividends.
What is Relmada Therapeutics’s EPS estimate?
Relmada Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Relmada Therapeutics have?
Relmada Therapeutics has 33,191,624 shares outstanding.
What happened to Relmada Therapeutics’s price movement after its last earnings report?
Relmada Therapeutics reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.46. Following the earnings report the stock price went down -1.667%.
Which hedge fund is a major shareholder of Relmada Therapeutics?
Currently, no hedge funds are holding shares in RLMD
Relmada Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (-37.50% Downside)
$1.00 (-37.50% Downside)
Hedge Fund Trend
Increased
By 740.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $178.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-47.19%
12-Months-Change
Fundamentals
Return on Equity
-175.12%
Trailing 12-Months
Asset Growth
-70.27%
Trailing 12-Months
Company Description
Relmada Therapeutics
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of central nervous system (CNS) diseases. The company is primarily engaged in the research and development of novel compounds and formulations aimed at addressing unmet medical needs within the CNS sector. Relmada's lead product candidate is REL-1017 (esmethadone), an NMDA receptor antagonist, which is being investigated for the treatment of major depressive disorder (MDD).
RLMD Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Relmada Therapeutics demonstrated significant progress in Phase II trials for NDV-01, added promising new product candidates, and improved cash management. However, challenges remain with a decreased cash balance and a notable net loss. Despite these challenges, the advancements in clinical trials and strategic team expansions paint a positive outlook.View all RLMD earnings summariesTechnical Analysis
Immuron
―
Bioxcel Therapeutics
―
Citius Pharmaceuticals
―
Hookipa Pharma
―
Athira Pharma
―
Ownership Overview
5.93% Insiders
2.01% Mutual Funds
5.93% Other Institutional Investors
83.36% Public Companies and
Individual Investors